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Abstract
Infections caused by Clostridium difficile have increased steadily over the past several years. While studies on C. difficile
virulence and physiology have been hindered, in the past, by lack of genetic approaches and suitable animal models, newly
developed technologies and animal models allow these processes to be studied in detail. One such advance is the
generation of a mouse-model of C. difficile infection. The development of this system is a major step forward in analyzing
the genetic requirements for colonization and infection. While important, it is equally as important in understanding what
differences exist between mice and humans. One of these differences is the natural bile acid composition. Bile acid-
mediated spore germination is an important step in C. difficile colonization. Mice produce several different bile acids that are
not found in humans. These muricholic acids have the potential to impact C. difficile spore germination. Here we find that
the three muricholic acids (a-muricholic acid, b-muricholic acid and v-muricholic acid) inhibit C. difficile spore germination
and can impact the growth of vegetative cells. These results highlight an important difference between humans and mice
and may have an impact on C. difficile virulence in the mouse-model of C. difficile infection.
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Introduction
Clostridium difficile is an anaerobic, spore-forming bacteria that is
the leading cause of antibiotic-associated diarrhea. As the costs
associated with treatment continue to rise [1,2], much research has
focused on understanding the normal course of infection within
humans. One of the challenges in the study of C. difficile infections
has been developing suitable animal models that adequately
reproduce symptoms as presented in humans. Gnotobiotic
neonatal piglets, rats, and germ-free mice have all been used to
varying degrees of success [3,4,5,6]. The most widely used model
has been the Syrian hamster model of C. difficile disease
[7,8,9,10,11]. Antibiotic-treated hamsters are very sensitive to C.
difficile infection with lethal disease presenting approximately 3
days after inoculation by C. difficile spores. While the hamster
represents an excellent model of acute disease, hamsters typically
succumb too quickly to disease to measure factors influencing
colonization, representing only the full presentation of disease and
not less severe symptoms when exposed to epidemic strains [12].
Such rapid progression of the disease and high mortality can also
pose problems when attempting to study relapsing infection.
Several mouse models of infection have been developed
[5,13,14,15,16,17]. Some of these models use heavy doses of
antibiotics (e.g. kanamycin, gentamicin, colistin, metronidazole
and vancomycin followed by clindamycin or cefoperazone
followed by clindamycin) and then inoculation with C. difficile
spores or vegetative cells [14,15]. These antibiotic regimens
sensitize mice so that they respond to infection in a dose dependent
manner (increasing disease severity with increasing number of
dosed cells or spores). Further, antibiotic-treated mice can relapse
after a course of antibiotic treatment, to cure the primary
infection, and will express some resistance to reinfection when
allowed to fully recover from disease [14]. These are important
components of an animal model because relapse in humans
represents one of the main challenges to current treatment
regimens [18,19].
Because the mouse model is beginning to be a more widely
accepted method of testing potential preventative therapies [20]
and the genetic requirements for infection [13,21,22], it is
important to understand what potential variability exists between
the mouse model of infection and humans. One potential source of
variability is the natural differences between mouse and human
microbiota. The use of an antibiotic cocktail before infection is an
attempt to impact these other microbes [23,24]. Another
important source of variability is the differences in the natural
fecal bile acid composition between mice [25,26] and humans [27]
(and hamsters [28,29,30]).
In humans, bile acids are synthesized in the liver as either cholic
acid (3a, 7a, 12a-trihydroxy-5b-cholanic acid) or chenodeoxy-
cholic acid [3a, 7a,-dihydroxy-5b-cholanic acid (CDCA)] [27].
These bile acids are then conjugated with either taurine or glycine
and, later, further modified by certain members of the colonic
microbiota [27]. Previous work has shown that colony formation
by C. difficile spores on rich medium occurs after exposure to cholic
acid derivatives [31,32]. Subsequent work has shown that all
cholic acid derivatives and some amino acids, commonly glycine,
can stimulate the initiation of spore germination while CDCA-
derivatives are competitive inhibitors of cholic acid-mediated
germination [31,33,34,35,36]. In mice and rats, CDCA is a
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component of bile, but there are two additional bile acids, a-
muricholic acid (AMA) and b-muricholic acid (BMA), that are not
present in humans [37]. A third muricholic acid, v-muricholic
acid (OMA), is an epimer of BMA and is produced by the normal
microbiota. The effects of these compounds on C. difficile spore
germination are unknown.
Germination by C. difficile spores must be the first step in
colonization [20,38]. The toxins necessary for disease are not
found within the spore or deposited on the outer layers during
spore formation [39]. To generate active infection in the hamster
model of C. difficile disease, approximately 100 spores will result in
a lethal infection (LD100) while in the mouse model, significantly
more spores are required to generate lethal disease (,108) [20].
Interestingly, when vegetative cells are used to inoculate antibiotic-
treated mice, fewer cells are needed (,105), suggesting the
efficiency of in vivo germination by C. difficile spores may be
affected differently in the mouse than in the hamster [14,20,40].
Here, we investigate how muricholic acids affect C. difficile spore
germination and growth using two C. difficile isolates; UK1– an
epidemic ribotype 027 isolate [34,41] and M68– a ribotype 017
that readily colonizes mice [13,17]. We find that all three
muricholic acids can inhibit C. difficile spore germination with
apparent affinities similar to what is observed for CDCA and that
these compounds are also growth inhibitory.
Materials and Methods
C. difficile Growth Conditions
C. difficile strain UK1 [34,38,41,42] and strain M68 [13,43]
were grown in BHIS medium (Brain Heart Infusion supplemented
with 5 g/L yeast extract and 0.1% L-cysteine) at 37uC in an
anaerobic environment (85% nitrogen, 10% hydrogen and 5%
carbon dioxide).
C. difficile Spore Preparations
Spores of C. difficile UK1 and C. difficile M68 were prepared as
described previously [34,42,43]. Briefly, C. difficile UK1 or M68
were streaked on BHIS agar medium and incubated for 4 days
under anaerobic conditions at 37uC. Plates were then removed
from the chamber and cell matter was scraped and diluted into
1 mL of water. Tubes were then left to incubate overnight at 4uC
to aid in the release of spores from the mother cell. The next day,
cell matter was resuspended and centrifuged at 14,0006g for 1
minute. Tubes were decanted and resuspended in 1 mL of water.
After 5 washes, the pellets from several tubes were combined in
2 mL water and layered on top of 8 mL of 50% sucrose. Spores
were separated from vegetative cells and cell debris by centrifu-
gation for 20 minutes at 4,0006g. All liquid was then removed
from the tube. The pellet, containing the purified spores, was
resuspended in 1 mL of water. The purified spores were washed in
water as described above. When examined by phase-contrast
microscopy, the remaining pellet appeared to be composed
.99.9% phase-bright spores.
Germination of C. difficile Spores
Purified spores were heat activated for 30 min at 65uC and
placed on ice, as described previously [33,34,42,44,45]. Heat-
activated spores were then diluted into 990 mL BHIS supplement-
ed with 0 mM, 2 mM, 5 mM, 10 mM, 20 mM or 50 mM
taurocholate. When testing muricholic acids or CDCA, bile
compound was added to tubes before the addition of spores. The
initiation of germination was followed by monitoring absorbance
at 600 nm. The ratio of the A600 at time6 (Tx) to the A600 at time
zero (T0) was plotted against time. Germination rates, and
apparent affinities, were determined using the slopes of the linear
portions of the germination plots, as described previously
[34,42,45]. Data are reported as the averages from three
independent experiments with one standard deviation from the
mean. For clarity, only every fourth data point is plotted. CDCA,
AMA, BMA and OMA were dissolved at 100 mM in 100%
ethanol. AMA, BMA and OMA were purchased from Steraloids,
Inc (Newport, RI).
Minimum Inhibitory Concentration
C. difficile, from an actively growing plate, was grown overnight
in 5 mL liquid BHIS under anaerobic conditions. The next day,
25 mL BHIS medium was inoculated with 0.25 mL of the
overnight C. difficile culture and then incubated until an OD600
of 0.45. One hundred twenty five-microliters of this culture then
added to 50 mL of ice cold reduced BHIS and kept on ice.
Microtiter plates containing BHIS and serially diluted compound
were previously prepared and placed in anaerobic chamber to
reduce. 10 mL of chilled cells were then added to wells and
incubated for 24 hours at 37uC. After 24 hours, plates were
removed from the anaerobic chamber and growth measured using
a BioRad Xmark plate reader.
Statistical significance. Experiments were performed in
triplicate and data represent the average of the three independent
experiments. Statistical significance between UK1 and M68 was
determined using the Student’s T-test.
Results
Structures of Muricholic Acids
Mice synthesize three bile acids not found in humans. Two of
these compounds are synthesized directly by the mouse; AMA (3a,
6b, 7a-trihydroxy-5b-cholanic acid) and BMA (3a, 6b, 7b-
trihydroxy-5b-cholanic acid) (Figure 1) [25,26]. The third
muricholic acid, OMA (3a, 6a, 7b-trihydroxy-5b-cholanic acid)
is produced by oxidation of the 6b-hydroxyl of b-muricholic acid
followed by reduction of the compound to a 6a-hydroxyl group
(Figure 1) by members of the mouse colonic microbiota [46,47].
AMA and BMA contain a 6b-hydroxyl group while OMA
contains a 6a-hydroxyl group (Figure 1). The conformational
effect of this 6-hydroxyl group is untested on C. difficile spore
germination because bile acids normally found in the human gut
lack the 6-hydroxyl group. As shown in Figure 1, all three
muricholic acids lack a 12a-hydroxyl group, suggesting they might
act as inhibitors of C. difficile spore germination [34].
Muricholic Acids Inhibit C. difficile Spore Germination
To understand how these compounds affect germination, C.
difficile spores were assayed for germination in the presence or
absence of muricholic acids. As positive and negative controls,
respectively, the initiation of spore germination was followed in the
presence of taurocholic acid, a known C. difficile spore germinant
[31,32] or in the presence of taurocholic acid and CDCA, a known
inhibitor of C. difficile spore germination [33,34].
Purified C. difficile UK1 spores were suspended in BHIS medium
and different taurocholic acid concentrations (Figure 2A). As
described previously, the rate of germination increased with
increasing taurocholic acid concentration [34,42,45]. The addition
of 1 mM CDCA had an inhibitory effect on germination
(Figure 2B). The addition of 1 mM AMA resulted in a clear
reduction of the ability of C. difficile spores to germinate in response
to TA (Figure 2C). The effect of this inhibition of germination was
quantified by applying Michaelis-Menten kinetics to the germina-
tion plots to generate apparent Km values. While not traditional
Inhibiting C. difficile Spore Germination
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enzyme kinetics, these types of analyses have aided in the
identification of the requirements for spore germination and for
novel inhibitors of spore germination [34,36,42,44,45,48,49,50].
Analysis of the Lineweaver-Burk plot of C. difficile UK1 spore
germination in taurocholic acid alone (Figure 2D) yielded an
apparent Km value similar to what has been previously reported
(Table 1) [34,42]. When analyzing germination by C. difficile UK1
spores in the presence of different muricholic acids, it was
immediately obvious that these compounds were germination-
inhibitory. From the germination plots, we determined the rates of
germination and used this data to generate apparent inhibitory
constants (Ki) for each inhibitor tested (Table 1). Comparing the
muricholic acids to CDCA, BMA and OMA yielded apparent
inhibition constants similar to CDCA while AMA proved to be
least efficient at inhibiting germination (Table 1). The difference
between CDCA and AMA can be observed by comparing the
ability of C. difficile spores to germinate in BHIS medium
supplemented with 2 mM TA. Addition of 1 mM CDCA had a
greater effect than did the addition of 1 mM AMA.
Germination of C. difficile M68 in medium with taurocholic acid
was similar to C. difficile UK1. C. difficileM68 rapidly germinated in
medium supplemented with taurocholic acid (Figure 3A) and was
inhibited when 1 mM AMA was added to the germination
solution (Figure 3B). However, by analyzing the kinetics of C.
difficile M68 spore germination, we observed that the data from
this strain produced non-linear Lineweaver-Burk plots (Figure 3C),
a phenomenon observed for some other C. difficile strains [45]. The
Hill plot (Figure 3D) was used to generate the apparent Km. This
value was then used to determine the apparent Ki under each
condition tested. When C. difficile M68 spores were germinated in
the presence of CDCA, germination was strongly inhibited
(Table 1). The inhibition of germination by BMA was similar to
the inhibition observed for C. difficile UK1 and, again, AMA was
the least efficient at inhibiting spore germination (Table 1). OMA
was a more potent inhibitor of C. difficile M68 spore germination
than C. difficile UK1 spore germination (p-value ,0.05).
Minimum Inhibitory Concentration of Muricholic Bile
Acids
Previously, we demonstrated that CDCA and deoxycholic acid
inhibited C. difficile growth [31]. In antibiotic-treated mice, the
levels of deoxycholic acid are likely to be very low because it is a
product of the 7a-dehydroxylation of cholic acid by the normal
microbiota [27]. However, cholic acid, CDCA, AMA and BMA
will be present and could affect C. difficile growth. To quantify the
effects of these compounds on C. difficile growth, we determined
the MIC. Serial, 2-fold dilutions of bile acids in growth media were
used determine the MIC for each bile acid (Table 2). C. difficile
strain UK1 did not grow in the presence of CDCA or AMA or
BMA, at a concentration of 1 mM or above. OMA was less toxic
to the strain; a concentration of 2 mM was necessary to inhibit
growth. In stark contrast, the MIC of cholic acid for C. difficile
UK1 was 10 mM, a concentration not found in the colon. We
observed slightly different results when analyzing the MIC of these
bile acids for C. difficile M68 growth. This strain was more resistant
to the toxic effects of AMA and BMA while equally as sensitive to
CDCA, cholic acid and deoxycholic acid (Table 2). BMA is more
prevalent in the gut of rats and mice than is CDCA [25,51],
suggesting that a strain which is more resistant to the toxic effects
of BMA (e.g. C. difficileM68) might be able to better colonize mice.
Discussion
In the laboratory setting, certain combinations of bile acids and
amino acids are the most effective conditions for measuring C.
difficile spore germination [31,32,35]. While cholic acid derivatives
can stimulate C. difficile spore germination [31], CDCA-derivatives
inhibit cholic acid-mediate germination by C. difficile spores
[33,34]. Compared to humans, mice produce a low level of
CDCA but produce other bile acids (AMA and BMA), in greater
abundance. These muricholic acids may have an impact on how
C. difficile spores germinate in vivo. Here, we found that AMA,
BMA and OMA (a microbial product) inhibit taurocholic acid-
mediated spore germination with BMA and OMA being the most
potent germination-inhibiting muricholic acids (Table 1). These
results are consistent with our previous work that has shown the
12-hydroxyl group to be an important determinant of whether a
compound functions as a germinant or inhibitor of germination
[31,33,34]. One difference observed between the germination of
C. difficile UK1 spores and C. difficileM68 spores was the non-linear
double-reciprocal plot for germination by C. difficile M68 spores.
As seen in other strains, C. difficile M68 may bind taurocholic acid
cooperatively [45]. With the recent identification of the molecular
target of bile acids on the C. difficile spore, this hypothesis could be
tested outright [38].
Total bile acid levels in the distal small intestine have been
estimated to be between 1 mM to 2 mM in concentration [52].
This is in the range of the concentrations which inhibit C. difficile
growth for the individual bile acids tested (Table 2); variations in
pH may affect the toxicity of each bile acid [53]. Comparing these
concentrations to the apparent Ki values determined for AMA and
BMA, they are approximately 36 to 86 greater, respectively
(Table 1). That is, in an antibiotic-treated mouse, the levels of
AMA and BMA might prevent efficient C. difficile spore
germination, possibly explaining why such greater numbers of
spores, compared to vegetative cells, are required to colonize a
Figure 1. Structures of common muricholic acids. The primary
bile acids (cholic acid, chenodeoxycholic acid, a-muricholic acid and b-
muricholic acid) are listed. Deoxycholic acid and v-muricholic acid are
secondary bile acids and are products of the normal microbiota.
doi:10.1371/journal.pone.0073653.g001
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mouse [20]. It is also important to note that most mice used as a
model for C. difficile infection would likely contain reduced levels of
OMA because its formation requires the presence of mouse gut
microbes [46,47] which are likely ‘collateral damage’ during a
routine course of broad-spectrum antibiotics.
Antibiotics can affect host functions. That is, treating mice with
antibiotics could lead to alterations in the bile acid spectrum and
increase or decrease the availability of activators or inhibitors of C.
difficile spore germination. Treatment of mice with antibiotics has
been shown to increase hepatic bile acid synthesis [54].
Specifically, the authors identified that small intestine, lumenal
concentrations of taurocholic acid, tauro-b-muricholic acid and
taurochenodeoxycholic acid were more abundant in antibiotic-
treated C57/BL6 mice than in vehicle-only controls [54]; the
authors did not measure the levels of AMA. Thus, upon antibiotic
exposure, an increase in the abundance of germination-inhibiting
bile acids could contribute to an environment which is more
resistant to C. difficile spore germination.
Some C. difficile strains have been shown to stably colonize mice
and enter a ‘contagious’ state, where disease is limited but spore
shedding is maintained, while other strains are cleared by the host
[13,17]. The mechanisms by which some C. difficile strains are able
to stably colonize a host while others do not, is unclear. While the
answer is likely to be multifactorial, an increased resistance to bile
Figure 2. a-muricholic acid inhibits germination by C. difficile UK1 spores. (A) Germination of Clostridium difficile UK1 spores in complex
medium supplemented with taurocholic acid (TA) or (B) medium supplemented with TA and 1 mM CDCA or (C) medium supplemented with TA and
1 mM a-muricholic acid. N 0 mM TA,& 2 mM TA, m 5 mM TA, . 10 mM TA,¤ 20 mM TA or# 50 mM TA. (D) The inverse rate (1/v [sec/OD600]),
versus the inverse taurocholate concentration (1/S [mM21], was plotted. Apparent Km values for TA alone (N) and in the presence of a-muricholic acid
(&) were determined from the linear best fit.
doi:10.1371/journal.pone.0073653.g002
Table 1. Bile acid effects on C. difficile spore germination.
Strain UK1 M68
Km (mM) Km (mM)
Taurocholic Acid 3.260.5 3.560.5
Ki (mM) Ki (mM)
Chenodeoxycholic Acid 0.2260.07 0.1260.02
a-Muricholic Acid 0.6260.09 0.5960.05
b-Muricholic Acid 0.2760.12 0.2660.02
v-Muricholic Acid 0.2960.03 0.2060.01*
Ki = [inhibitor]/[(Km,TA with inhibitor)/((Km,TA without inhibitor) 21)].
*p,0.05.
doi:10.1371/journal.pone.0073653.t001
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acids could contribute to a strain’s ability to persist within a host.
C. difficile M68 is a strain that can enter a supershedder state after
the cessation of antibiotic treatment [13]. We find C. difficile M68
to be more resistant to bile acid toxicity than is C. difficile UK1 and
this increased resistance may aid C. difficile M68 in maintaining
active colonization.
Muricholic acids might provide a level of protection to mice
from C. difficile infection that is not seen in other models of C.
difficile disease. While our results suggest that particular bile acids
may inhibit C. difficile spore germination or vegetative growth
in vitro, it is unclear if AMA or BMA could substitute for each other
in preventing in vivo spore germination. Clearly, BMA is a more
potent inhibitor of in vitro spore germination than is AMA. But,
given the vast repertoire of mouse lines and genetic approaches,
testing the ability of C. difficile to colonize mice that have had
introduced mutations into specific steps in the bile acid/muricholic
acid synthesis pathway would allow the determination of which
bile acids are relevant for stimulating or inhibiting in vivo spore
germination and vegetative growth.
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